Clinical Trials in Tugun, Australia
2 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Heart Failure
Boehringer Ingelheim6,000 enrolled653 locationsNCT06424288
Recruiting
Phase 2Phase 3
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Unresectable Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerRecurrent Head and Neck Cancer
BioNTech SE350 enrolled193 locationsNCT04534205
Recruiting
Phase 3
A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)
Breast Neoplasm FemaleRadiotherapyCosmetic Outcome
Ontario Clinical Oncology Group (OCOG)910 enrolled28 locationsNCT05417516
Recruiting
Phase 1
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
Advanced Solid Tumors
Shandong Suncadia Medicine Co., Ltd.100 enrolled6 locationsNCT06770569
Recruiting
Phase 2Phase 3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics650 enrolled129 locationsNCT06788990
Recruiting
Phase 2
YN001-004 in Patients With Coronary Atherosclerosis in Australia
Coronary Artery DiseaseCoronary Atherosclerotic Disease
Beijing Inno Medicine Co., Ltd.24 enrolled7 locationsNCT06700720
Recruiting
Phase 1Phase 2
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Gilead Sciences100 enrolled16 locationsNCT06926920
Recruiting
Phase 1
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
Neoplasms
GlaxoSmithKline84 enrolled6 locationsNCT07277270